20 Jul S. Biomedics
Saeil (Tony) Kang, President and CEO
Oct. 8 | 4:45pm | FLW Ballroom F
Seoul, Korea
(KOSDAQ: 304360)
S.Biomedics is one of South Korea’s leading cell medicine corporation focusing on regenerative medicine. Through two robust platform technologies, 7 cell therapy programs are under development with 4 programs under clinical stage. One notable success is the development of TED-A9, a promising treatment for Parkinson’s Disease by utilizing hESC derived ventral-midbrain specific dopamine precursors. Promising results in the in-vitro and in-vivo studies were published on “Cell Stem Cell” on December 2023. TED-A9 is currently in Phase 1/2a in Korea for 12 patients, and all 12 patients were administered. Mid-term data of the study is expected to be released this year. Furthermore, TED-N (hESC derived NPC for SCI Phase 1/2a) and FECS-Ad (MSC spheroid for CLI Phase 1/2a) are under development.
